Investor Information

Radiologists look at MRI scans and use their extensive training to make qualitative judgments, but they don't yet extract all possible information from the data. Quantitative measurements of volume, shape, and location can be used as biomarkers or surrogate endpoints to help in the diagnosis, identification of subtypes, and in guiding and gauging response to treatment of disorders such as alcoholism, schizophrenia, epilepsy, multiple sclerosis, Alzheimer’s disease, cancer, autism, attention-deficit hyperactivity disorder, post traumatic stress disorder, and many others. Using quantitative image-based biomarkers will save time and money and open up new possibilities for understanding and treating these disorders.

Neuromorphometrics' expertise is in localizing and delineating anatomy as it appears in MR brain scans. Given raw scans, we make precise quantitative measurements of the volume, shape, and location of specific neuroanatomical structures. We are in the final stages of developing our new automated brain analysis system, which will become the benchmark for the treatment and diagnosis of brain disorders measured quantitatively from MRI scans. We are seeking a partner or investor to help us speed the process of bringing automated analysis into the rapidly expanding field of quantitative medical imaging.

More...